Immunological heterogeneity of the RCC microenvironment: Do targeted therapies influence immune response?

Current Oncology Reports

Volumn 14, Issue 3, 2012, Pages 230-239

  Bex, Axel ^a   Etto, Tamara ^b   Vyth Dreese, Florry ^a   Blank, Christian ^a   Griffioen, Arjan W ^c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MONASH UNIVERSITY   (Australia)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Genitourinary cancer; Immune response; Immunology; Metastatic renal cancer; Microenvironment; Subtypes; Targeted therapy

Indexed keywords

AGS 003; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMA 901; IMMUNOMODULATING AGENT; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL INTERACTION; CELLULAR IMMUNITY; CYTOREDUCTIVE SURGERY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EXPERIMENTAL STUDY; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; IN VITRO STUDY; KIDNEY CARCINOMA; LEWIS CARCINOMA; LOW DRUG DOSE; MACROPHAGE MIGRATION; MONOTHERAPY; MYELOID DERIVIED SUPPRESSOR CELL; NEPHRECTOMY; NONHUMAN; OVERALL SURVIVAL; QUANTITATIVE STUDY; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SUPPRESSOR CELL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; DRUG EFFECT; IMMUNOLOGY; KIDNEY TUMOR; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW; T LYMPHOCYTE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84864014138     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0229-9     Document Type: Article

References (67)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
2. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol. 2011;60(1):1-15.
3. Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19 (2):98-102.
4. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2010;77(1):48-62.
5. Vogelzang NJ, Samlowski W, Weissman A. Long-term response in primary renal cancer to sequential antiangiogenic therapy. J Clin Oncol. 2009;27(26):e106-7.
6. Oudard S. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res. 2010;30(12):5223-5.
7. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): A Cochrane systematic review of published randomised trials. BJU Int. 2011;108 (10):1556-63.
8. Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, et al. ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of metastatic disease. Eur Urol. 2011;60(4):684-90.
9. Bex A, Haanen J. Tilting the AXIS towards therapeutic limits in renal cancer. Lancet 2011(in press).
10. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: An in situ tumor vaccine? J Urol. 2003;170(1):178-9.
11. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49 (5):798-805.
12. Atzpodien J, Reitz M. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. Cancer Biother Radiopharm. 2005;20(4):410-6.
13. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293-301.
14. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005;1:CD001425.
15. Keller AM, Borst J. Control of peripheral T cell survival: A delicate division of labor between cytokines and costimulatory molecules. Hum Immunol. 2006;67(6):469-77.
16. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-96.
17. • Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD. Cross-talk between tumor and myeloid cells: How to tip the balance in favor of antitumor immunity. Immunotherapy. 2011;3(1):77-96. An important overview of myeloid-derived suppressor cells and their function.
18. Denardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54-67.
19. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119(2):317-27.
20. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-45.
21. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381-5.
22. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14(16):5150-7.
23. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103(27):10391-6.
24. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41-51.
25. Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010;70(19):7455-64.
26. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011;102(7):1424-31.
27. Menke J, Kriegsmann J, Schimanski CC, Schwartz MM, Andreas S, Kelley VR. Autocrine CSF-1 and CSF-1 receptor co-expression promotes renal cell carcinoma growth. Cancer Res 2011(in press).
28. Molema G, Griffioen AW. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol Today. 1998;19(9):392-4.
29. Griffioen AW, Vyth-Dreese FA. Angiostasis as a way to improve immunotherapy. Thromb Haemost. 2009;101(6):1025-31.
30. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008;118(10):3367-77.
31. Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: Implications for cancer treatment. Immunotherapy. 2011;3(2):213-27.
32. Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol. 2007;178(4):2163-70.
33. •• Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514-22. Landmark preclinical study demonstrating that c-kit ligand is required for MDSC accumulation and Treg development and that sunitinib reverses this process.
34. •• Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70(9):3526-36. Important preclinical study demonstrating MDSC suppression by sunitinib is constraint to compartments and may be regulated by GM-CSF.
35. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171-80.
36. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009;100(7):1111-9.
37. •• Gu Y, Zhao W, Meng F, Qu B, Zhu X, Sun Y, et al. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol. 2010;135(1):55-62. In vitro study demonstrating the effect of sunitinib on human peripheral T cells.
38. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14(20):6674-82.
39. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008;111 (12):5610-20.
40. • Busse A, Asemissen AM, Nonnenmacher A, Braun F, Ochsenreither S, Stather D, et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur J Cancer. 2011;47(5):690-6. One of the very few studies investigating the effect of sorafenib on immune effector cells in humans with mRCC.
41. •• Adotevi O, Pere H, Ravel P, HaicheurN, Badoual C, Merillon N, et al. A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. J Immunother. 2010;33(9):991-8. A study in humans with mRCC in whom sunitinib decreased Treg, which correlated with overall survival.
42. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+dendritic cell frequency predicts progression-free survival. Clin Cancer Res. 2008;14(18):5884-92.
43. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148-57.
44. Mulder SF, Jacobs JF, Olde Nordkamp MA, Galama JM, Desar IM, Torensma R, et al. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res. 2011;17(13):4541-9.
45. Bex A, Jonasch E, Vyth-Dreese F, de Hoog C, Dellemijn T, Griffioen AW. Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue. J Clin Oncol 2010; 28(15s):(suppl, abstract 4607).
46. • Desar IM, Jacobs JFM, Hulsbergen-vandeKaa CA, Oyen WJ, Mulders PF, van der Graaf WT, et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer. 2011;129(2):507-12. One of the very few studies investigating the effect of sorafenib on immune effector cells in humans with mRCC.
47. •• Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11(7):856-61. A study in humans building on the preclinical work on the compartmental differences of MDSC-suppression by sunitinib reported in [34••].
48. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 1996;88(2):667-73.
49. Griffioen AW, Damen CA, Mayo KH, Barendsz-Janson AF, Martinotti S, Blijham GH, et al. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int J Cancer. 1999;80(2):315-9.
50. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2(9):992-7.
51. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect. 1996;92:65-82.
52. Dirkx AE, Oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006;20(6):621-30.
53. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-81.
54. Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, et al. Phase I trial of sunitinib malate plus interferonalpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7(1):28-33.
55. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): A randomised phase 2 trial. Lancet Oncol. 2011;12 (7):673-80.
56. US National Institutes of Health. Study Comparing Bevacizumab+ Temsirolimus vs. Bevacizumab+Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). Available from: Http:// clinicaltrials.gov/ct2/show/ NCT00631371 (Last accessed Oct 10, 2011). ClinicalTrials gov 2008.
57. Amin A, Dudek A, Logan T, Lance RS, Holzbeierlein JM, Williams WL, et al. A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J Clin Oncol 2010; 28(15s(suppl;abstr 4588)).
58. Figlin RA, Nicolette CA, Amin A, Dudek A, Logan T, Lance RS, et al. Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J Clin Oncol 2011; 29((suppl; abstr 2532)).
59. US National Institutes of Health. BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC). Available from: Http://clinicaltrials.gov/ct2/show/ NCT01354431 (Last accessed October 10; 2011). ClinicalTrials gov 2009.
60. US National Institutes of Health. Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib (rcc). Available from: Http://clinicaltrials.gov/ct2/show/NCT00890110 (Last accessed October 10; 2011). ClinicalTrials gov 2009.
61. US National Institutes of Health. IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma. Available from: Http://clinicaltrials.gov/ct2/show/NCT01265901 (Last accessed October 10; 2011). ClinicalTrials gov 2010.
62. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-75.
63. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233-40.
64. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115(6):1616-26.
65. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, et al. Multicenter, randomized, phase III trial of CD8 (+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17(8):2521-9.
66. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J Clin Oncol. 1995;13(8):1939-49.
67. Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, et al. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res. 2009;29 (1):145-54.